Drug Patent Watch
JUNE 25, 2024
DrugChatter is an innovative AI-powered search and answer engine designed to revolutionize how we access and comprehend information. Harnessing the power of advanced natural language processing, DrugChatter provides concise, accurate, and contextually relevant answers to a wide array of questions, making information retrieval faster and more intuitive than ever before.
Bio Pharma Dive
JUNE 25, 2024
The company claims it can address some of the field’s limitations with medicines delivered via messenger RNA and lipid nanoparticles.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JUNE 25, 2024
Novo Nordisk has unveiled a significant investment plan, committing $4.1bn to construct a second fill and finishing facility in Clayton.
AuroBlog - Aurous Healthcare Clinical Trials blog
JUNE 25, 2024
Artificial intelligence (AI) is transforming healthcare customer experience as healthcare organisations are uniquely challenged to provide great customer service in stressful and highly personal situations, says Vasudeva Rao Munnaluri, regional vice president (RVP) for India & SAARC at Zendesk while discussing the role of AI in healthcare customer experience (CX) and the unique challenges faced […]
Pharmaceutical Technology
JUNE 25, 2024
Merck’s decision follows the independent committee's analysis that the trial is unlikely to meet its primary endpoints.
Bio Pharma Dive
JUNE 25, 2024
The company plans to make a case to regulators for a new accelerated approval pathway. But investors didn't seem as hopeful, sending shares down by double digits.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Bio Pharma Dive
JUNE 25, 2024
The planned facility in North Carolina is Novo’s latest multibillion-dollar investment in the manufacturing of weight loss drugs, demand for which continues to outstrip supply.
Pharmaceutical Technology
JUNE 25, 2024
Discover the critical factors in choosing medical packaging companies for pharmaceutical contract manufacturing. Ensure quality with our guide.
BioSpace
JUNE 25, 2024
Following in the footsteps of Sanofi and Moderna, Eli Lilly on Tuesday inked a collaboration agreement with OpenAI to develop novel antimicrobial agents against drug-resistant pathogens.
Pharmaceutical Technology
JUNE 25, 2024
GSK has received approval from the Japan's Ministry of Health, Labour and Welfare (MHLW) for Omjjara to treat patients with myelofibrosis.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Fierce Pharma
JUNE 25, 2024
A little over a year after being slapped with an FDA rejection, AbbVie has hit another regulatory wall in its bid to debut a more convenient Parkinson’s disease successor to its established fo | A little over a year after being slapped with an FDA rejection, AbbVie has hit another regulatory wall in its bid to debut a more convenient Parkinson’s disease successor to its established formulation of carbidopa and levodopa.
Pharmaceutical Technology
JUNE 25, 2024
Explore the critical aspects of pharma packaging solutions, design, and companies. What to look for to ensure product safety and compliance.
XTalks
JUNE 25, 2024
The demand for food and beverage products with less sugar is rapidly increasing. Consumers are becoming more health-conscious, driven by a desire to avoid the negative health impacts associated with high sugar consumption, such as obesity and diabetes. As a result, food manufacturers are under pressure to find effective sugar reduction solutions to meet this demand.
Pharmaceutical Technology
JUNE 25, 2024
Oncoinvent has received FDA fast track designation for its therapy, Radspherin, to treat peritoneal metastases from ovarian cancer.
Fierce Pharma
JUNE 25, 2024
On the market for three years in China, Novo Nordisk’s diabetes drug Ozempic (semaglutide) is racing toward blockbuster sales in the world’s second most populous country. | China’s National Medical Products Administration (NMPA) has blessed Novo Nordisk's Wegovy with marketing approval to treat people with a body mass index (BMI) of at least 30 or between 27 and 30 for those with one weight-related risk factor.
Pharmaceutical Technology
JUNE 25, 2024
ETH47 is a type III interferon-encoding mRNA drug that could be used to treat respiratory diseases including uncontrolled asthma.
Fierce Pharma
JUNE 25, 2024
In the U.S. Federal Trade Commission’s (FTC) latest campaign against what the agency views as “junk” drug patents listed at the FDA, drugmakers have decided not to play ball. | In the U.S. Federal Trade Commission’s latest campaign against what the agency views as “junk” drug patent listings in the FDA’s database, drugmakers have decided not to play ball.
Pharmaceutical Technology
JUNE 25, 2024
At the Outsourcing in Clinical Trials UK and Ireland Conference, prominent figures in UK healthcare highlighted areas for change.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
pharmaphorum
JUNE 25, 2024
Explore the complexities of patient support in the realm of cell and gene therapies. Learn about the challenges and strategies for providing effective patient assistance in this cutting-edge field.
Drug Patent Watch
JUNE 25, 2024
Introduction: The United States Patent and Trademark Office (USPTO) has recently released a comprehensive study on drug patents and exclusivity trends in the pharmaceutical industry. The report, titled “USPTO Drug Patent and Exclusivity Study Report,” provides valuable insights into the patent landscape, patent duration, and exclusivity trends that shape the pharmaceutical industry.
pharmaphorum
JUNE 25, 2024
A survey of pharma industry executives has found that a third of them believe mistrust in the healthcare system has become a significant barrier to getting a diverse range of people to sign up for clinical trials.
BioPharma Reporter
JUNE 25, 2024
Once monthly treatment with Novo Nordiskâs antibody treatment reduced annual treated bleeds to zero in 95% previously untreated people with hemophilia A.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
pharmaphorum
JUNE 25, 2024
Two years ago, Merck KgAA was talking up xevinapant as a leap forward in head and neck cancer and one of the brightest stars in its late-stage pipeline, Now, the drug has been abandoned after failing a phase 3 trial.The TrilynX study was testing xevinapant with chemoradiotherapy in patients with unresected locally advanced squamous cell carcinoma of the head and neck (LA SCCHN), but according to an interim look at the data was unlikely to meet its goal of extending event-free survival.
Fierce Pharma
JUNE 25, 2024
While patients with low potassium often need medication to boost levels of the electrolyte in the body, too much of a good thing can cause serious health concerns. | Glenmark Pharmaceuticals on Tuesday said it’s recalling 114 batches of 750mg potassium chloride extended-release capsules thanks to failed dissolution of the product. Failed dissolution of the capsules could cause patients to develop heightened potassium levels, also known as hyperkalemia, which can result in irregular heartbeat.
pharmaphorum
JUNE 25, 2024
Discover practical use cases and common concerns surrounding the implementation of generative AI (GenAI) in clinical trials. Learn how this technology is transforming the landscape of medical research.
Fierce Pharma
JUNE 25, 2024
AstraZeneca’s Imfinzi can’t have it all. | While the PD-L1 inhibitor posted a clinical win in muscle-invasive bladder cancer, it also chalked up a failure in early-stage non-small cell lung cancer.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
pharmaphorum
JUNE 25, 2024
Almost half of young adults who participated in a UK survey said they had made a health decision they regret based on misinformation
BioSpace
JUNE 25, 2024
Zealand Pharma is looking to build on last week’s positive Phase Ib trial results by raising around $1 billion in a public offering, with the proceeds being used to advance its obesity candidates.
pharmaphorum
JUNE 25, 2024
AstraZeneca’s hopes of positioning Imfinzi as a post-surgery therapy for people with early-stage NSCLC have taken a knock
BioPharma Reporter
JUNE 25, 2024
Last week, OSP had the pleasure of speaking with Ginny Beakes-Read at the DIA Global conference.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Expert insights. Personalized for you.
105 
Let's personalize your content